IRIgor D. Romanov

Igor D. Romanov

*This is an algorithmically generated author record based on publicly available information.

Igor D. Romanov has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative Evaluation of Parenteral Chondroprotectors

    by I.D. Romanov, O.A. Shavlovskaya, I.A. Bokova

    In osteoarthritis treatment, chondroprotectors are prescribed, the purpose of which is to stop the destruction of the cartilage structure during the progression of the disease. But not all drugs that belong to the chondroprotectors group have the proper qualities: there is a standardized active substance in the composition, there are studies to evaluate pharmacokinetics, there is a valid code in the anatomical-therapeutic-chemical classification of the WHO (at Dec 27, 2024), medicinal product has both symptomatic and structurally modifying effects, only a long course is effective. therapy. Standardized active substance include chondroitin sulfate: it has a standardized active substance, studied pharmacokinetics, is present in the international classification of anatomicaltherapeuticchemical, and has a high level of proven efficacy with prolonged use due to its symptomatic and structural effects.

  • Open Access

    Consistent use injectable and oral chondroprotectors in patients with osteoarthritis and lower back pain. Case report

    by Olga A. Shavlovskaya, Igor D. Romanov, Irina A. Bokova

    Osteoarthritis (OA) is a disease of the entire joint, including structural changes in hyaline articular cartilage, subchondral bone, ligaments, capsule, synovial membrane and periarticular muscles. One of the causes of the development of nonspecific chronic lower back pain (LBP) is OA of the facet joints. In the treatment of OA and LBP against the background of OA facet joints, the chondroprotective agents are widely used: chondroitin sulfate (CS), glucosamine sulfate, undenatured type II collagen and their combinations. The aim of the article is to systematize the possibilities of practical application of Chondroguard TRIO® in patients with OA of different phenotypes and different localization. The experience of sequential administration of CS in patients (n=11) with OA and LBP with comorbid diseases is presented. At the initial stage of therapy, CS (Chondroguard®) was prescribed intramuscularly according to the scheme, then CS was prescribed perorally as part of a pharmaconutraceutical (Chondroguard® TRIO). The original pharmaconutraceutical Chondroguard® TRIO contains recommended doses of CS (1200 mg), glucosamine sulfate (1500 mg), undenatured type II collagen (40 mg). Clinical cases of the use of sequential administration of chondroprotectors (stage 1 – intramuscularly Chondroguard®, stage 2 – perorally Chondroguard® TRIO) demonstrate the clinical effectiveness of the proposed treatment regimen in patients of different age groups and OA phenotypes (posttraumatic, metabolic).


  • Retrospective Comparative Analysis of Chondroprotective Therapy Effectiveness in Chronic Lower Back Pain Patients

    by O.A. Shavlovskaya, I.D. Romanov, Moscow «Md-Clinic» Medical Centers, I.A. Bokova

    INTRODUCTION. The choice of optimal therapy for chronic lower back pain includes: influence on all links of the pain vicious circle, has analgesic and anti-inflammatory effects, chondroprotective effect. AIM. A retrospective comparative analysis of outpatient records of patients with chronic lower back pain with a course of therapy with drugs containing chondroitin sulfate – Chondroguard, and bioactive concentrate of small marine fish – Alflutop. MATERIAL AND METHODS. Outpatient records of patients who took Chondroguard and Alflutop in the period from January 2022 to April 2024 were included. Data from 60 patients (medium age 51.5±9.7 years). Patients were retrospectively divided into two groups depending on the strategy of pain management. The main group (n=30; medium age 51.0±9.8 years), who received Chondroguard intramuscularly (I/ m) every other day No. 25 according to the scheme: the first 3 injections (1st, 3rd, 5th day) - 1 ml (100 mg), with good tolerability from the 4th injection (7 day) – 2 ml (200 mg); and the Comparison group (n=30; medium age 49.3±9.9 years), received Alflutop 2 ml, 1 time a day, every other day, a short course of 10 days. The dynamics of the condition was assessed on days 10, 20, 50. RESULTS AND DISCUSSION. By day 50 in the Main group, there was a decrease in pain by an average of 86.6% according to the numerical rating scale and an improvement in the functional status according to the Oswestry scale of 95.5%, in the comparison group there was a decrease in pain by an average of 77.2%, an improvement in the functional status according to Oswestry scale of 86.7%. By day 50, the severity of pain syndrome in the Main group decreased by 91.2%, in the Comparison group – by 33.9%; indicators of the functional status of Oswestry scale in the Main group improved by 97.3%, in the Comparison group – by 84.8%. In the Main group, the need for multiple nonsteroidal anti-inflammatory drugs on the 10th day of therapy decreased to 1 tablet per day in 76.7%, in the Comparison group – in 16.7%. In the main group, after a course of therapy for 21.3±2.2 months. they did not consult a doctor in the comparison group after 5.3±1.1 months. A second course of therapy was conducted. CONCLUSION. In the Main group, the effects of therapy can be regarded as long-term, since the effects of highly purified chondroitin sulfate on the pathogenetic mechanisms of the formation of chronic lower back pain remain. KEYWORDS: pain syndrome, lower back pain, chondroitin sulfate, Chondroguard


  • Evidence base of pharmaconutraceuticals with chondroprotective action

    by O.A. Shavlovskaya, I.D. Romanov, I.A. Bokova

    Background. Osteoarthritis is one of the most common chronic diseases of the musculoskeletal system worldwide, being a common cause of chronic pain syndrome and disability. A number of pharmaconutraceuticals include well-known molecules, such as chondroitin sulfate, glucosamine sulfate, undenatured type II collagen, have proven effects on articular cartilage, subchondral bone, synovia. The use of these molecules makes it possible to influence main links in pathogenesis of osteoarthritis, and ultimately can slow down the progression of the disease, improve the quality of life of patients. Promising molecules for the prevention of osteoarthritis and a number of osteoarthritis diseases, along with chondroitin sulfate and glucosamine sulfate, are vitamin D3 and K2. One of the most important functions of vitamin D (25(OH)D) is to maintain the proper level of mineralization of the skeleton. By reducing 25(OH)D concentration in blood serum below optimal values leads to an increased risk of fractures, especially in the elderly. Vitamin K2, being a cofactor of osteocalcin carboxylation, improves bone mineral density and increases their strength. Сhondroitin sulfate, glucosamine sulfate, undenatured type II collagen block the activity of proinflammatory cytokines, stimulate the activity of osteoblasts and reduce the excessive activity of osteoclasts. The molecules of chondroitin sulfate, glucosamine sulfate, vitamin D3, and vitamin K2 have proven clinical efficacy and safety against osteoarthritis. Conclusion. Up to date, the molecules of chondroitin sulfate, glucosamine sulfate, undenatured type II collagen and vitamin D3 can be classified as to Disease Modifying Anti-Osteoarthritis Drug (DMOADs) that have both symptom-modifying and structural-modifying effects. Сhondroitin sulfate, glucosamine sulfate, vitamin D3 and K2 are prescribed for the treatment and prevention of diseases of musculoskeletal system. They can be presented both in the form of medicinal preparations and as part of biologically active food supplements. The use of these components may be warranted in patients with osteoarthritis and comorbidities (e.g., cardiovascular, type 2 diabetes mellitus).


  • Open Access

    Choline alfoscerate in the correction of cognitive impairment

    by O. A. Shavlovskaya, I. D. Romanov, I. A. Bokova

    In preclinical and clinical studies, choline alfoscerate (CA) has proven to be highly effective in the correction of cognitive impairment (CI). The clinical effect of CA is seen in the improvement of mental activity, concentration, ability to remember and recall information, cognitive and behavioural responses, elimination of emotional instability and apathy. Experimental studies have shown the effectiveness of CA in preventing atrophic changes in the cerebral cortex. Based on several studies conducted on the use of CA in the treatment of CI, it can be concluded that oral administration of CA at a dose of 600 mg/day can be recommended both as monotherapy and as part of complex therapy in patients with cerebrovascular diseases such as chronic cerebral ischemia. As part of complex therapy for CI in Alzheimer's disease, a combination of CA at a dose of 1200 mg/day with donepezil at a dose of 10 mg/day may be recommended. Several studies have demonstrated the efficacy of CA in the treatment of post-COVID and post-traumatic CI. The efficacy of CA administration in the treatment of CI (including vascular dementia) following ischemic stroke and transient ischemic attacks has been demonstrated. When CA is taken, there is also a reduction in anxiety and depressive disorders, asthenia, the severity of pain symptoms and changes in coordination. The duration of therapy should be 60 to 90 days, depending on the severity of CI, followed by an observation phase of up to 2 years. For successful treatment with CA, it is necessary to carry out repeated courses of CI treatment. Today, a new drug Cerpechol (600 mg/7 ml) has appeared on the Russian market, which has all the effects of CA. The convenience of the new form (oral solution) makes it possible to use it in patients with swallowing disorders.


  • Open Access

    Admitting a patient with musculoskeletal pain following COVID-19 disease

    by I. D. Romanov, O. A. Shavlovskaya, I. A. Bokova

    A significant proportion of patients who have had COVID-19 continue to suffer from persistent symptoms such as severe weakness, shortness of breath, joint pain, mood swings and memory impairment during the recovery phase. More than half of the patients experienced joint pain for the first time after recovery from COVID-19. Three months after COVID-19 episode, joint pain continued to occur in more than a third of patients. We observed a 47-year-old patient with moderate shoulder pain that occurred for the first time after COVID-19. The examination also revealed changes in the hip joint. The diagnosis was made: post-COVID syndrome with reactive arthritis of the left shoulder joint, deforming osteoarthritis of the left hip joint stage I, degenerative-dystrophic changes in the lumbosacral spine, lower back pain. The therapy was prescribed – Chondroguard® intramuscularly every other day according to the following scheme: the first three injections (day 1, 3, and 5) 1 ml (100 mg), then, from the fourth injection (day 7) – 2 ml (200 mg) every other day, a course of 30 injections. Positive dynamics were achieved. No adverse events were noted during the treatment. The patient continued taking the nutraceutical Chondroguard® TRIO orally for 2 months. During the observational period, no adverse events were noted. Thus, in cases where post COVID-19 musculoskeletal pain is caused by joint involvement, chondroprotective therapy is effective: stage 1 – injections, stage 2 – oral therapy.


  • Open Access

    Pharmaconutraceutical Chondroguard®TRIO – chondroprotector with immunomodulatory activity

    by O. A. Shavlovskaya, Yu. D. Yukhnovskaya, I. D. Romanov, I. A. Bokova

    Understanding the major pathological pathways and the key molecules involved in the pathogenesis of inflammatory processes in joints, particularly in osteoarthritis (OA), is crucial for drug and pharmaconutraceuticals development. OA is a degenerative joint disease that predominantly affects articular cartilage. Destruction of hyaline cartilage and restructuring of subchondral bone are accompanied by synovial inflammation in the joint, including the facet joint of the spine, manifested by pain in the joint, low back pain (LBP), and limitation of functional activity. The article discusses the relationship between immune and inflammatory mechanisms in OA of any location, including the joints of the spine. One of the mechanisms for the formation of a “vicious circle of inflammation” during the activation of discoidin receptors by endogenous type II collagen is discussed, leading to the induction of the synthesis of pro-inflammatory mediators: tumor necrosis factor α(TNFα), metalloproteinases (MMPs) 1 and 13, interleukins (IL) 1 and 6. Inflammation, in turn, leads to a decrease in the synthesis and destruction of endogenous type II collagen and, subsequently, to cartilage destruction. Cartilage fragments entering the joint space of the intercellular matrix enhance the synthesis of TNFα, IL, and MMP and exacerbate the inflammatory process. Oral ingestion of exogenous undenatured type II collagen(NK-II) helps, first, to inactivate the binding of fragments of destroyed endogenous type II collagen to discoidin receptors and to break the "vicious circle of inflammation"; secondly, through the mechanism of oral/intestinal tolerance via the lymphoid system in Peyer's patches of the small intestine, leads to the activation of immune cells (T-lymphocytes) and initiation of the immune response – the synthesis of anti-inflammatory mediators (transforming growth factor β, IL4 and IL10). The new pharmaconutraceutical Chondroguard®TRIO, which contains chondroprotectors (chondroitin sulfate and glucosamine sulfate) as well as NK-II, will make it possible to influence the key sites of the pathological process in OA.


  • Evaluation of the Possibility of Replacement of an SCh24 Cast Iron of Detail of a “Brake Disc” of a Car by an Aluminum-Based Dispersion-Strengthened Composition Material Prepared by Internal Oxidation

    by E. A. Chernyshov, A. D. Romanov, I. D. Romanov, L. A. Krivina, I. N. Tsareva

    This paper describes the results of the development of functional material represented by a dispersion-strengthened composition material based on aluminum